IrelandTuberculosis profile
Population  2015 4.7 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.017 (0.017–0.017) 0.36 (0.36–0.36)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.05 (0.03–0.08)
Incidence  (includes HIV+TB) 0.34 (0.29–0.39) 7.2 (6.2–8.3)
Incidence (HIV+TB only) 0.014 (0.011–0.018) 0.31 (0.24–0.39)
Incidence (MDR/RR-TB)** <0.01 (0–0.011) 0.08 (0–0.23)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.011 (<0.01–0.017) 0.13 (0.094–0.16) 0.14 (0.099–0.18)
Males 0.015 (0.01–0.02) 0.18 (0.14–0.22) 0.2 (0.15–0.24)
Total 0.026 (0.019–0.033) 0.31 (0.28–0.34) 0.34 (0.29–0.39)
TB case notifications, 2015  
Total cases notified 312
Total new and relapse 295
          - % tested with rapid diagnostics at time of diagnosis 0%
          - % with known HIV status 25%
          - % pulmonary 67%
          - % bacteriologically confirmed among pulmonary 73%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.06 (0.05–0.07)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 7 10%
          - on antiretroviral therapy 2 29%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  2
(0–6)
Estimated % of TB cases with MDR/RR-TB 1.1% (0.03–5.8) 0% (0–31)  
% notified tested for rifampicin resistance 45% 71% 190
MDR/RR-TB cases tested for resistance to second-line drugs   1
Laboratory-confirmed cases MDR/RR-TB: 1, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 1, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 56% 288
Previously treated cases, excluding relapse, registered in 2014 48% 21
HIV-positive TB cases, all types, registered in 2014 47% 17
MDR/RR-TB cases started on second-line treatment in 2013 33% 3
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-08 Data: www.who.int/tb/data